Bruce Spohler
Analyst · KBW. Your line is now open
Thank you, Rich. Before diving into the details of our portfolio and our fourth quarter activity I’d like to take a moment to just set the table and review our diversified origination platform. As most of you know, we spend this past several years building and attracting specialty finance lending businesses to our platform in order to advance our strategic objective of becoming diversified commercial finance company that has expertise across both cash flow and assets based underwriting. Today, we have four core business lines, our largest is our cash flow business, which invest in senior secured loans to sponsor back companies in the upper mid-market with average EBITDA of approximately $65 million, included in this vertical our assets held on balance sheet as well as in our SSLPs. Our second line to business is our asset based business, which encompasses non-traditional senior secured asset based loans both to companies in transition as well as loans to other finance companies. Much of this is invested through our 100% owned subsidiaries Crystal Financial, as well as directly on SLRC’s balance sheet. These loans are typically made against the realizable liquidation value of a portfolio company’s assets, and these loans also come with meaningful upfront and prepayment fees. Our third vertical is life science lending, which lends to privately held or small market cap drug and medical device companies. Our team previously founded and managed GE Capital’s life science lending business before joining Solar. These loans are made to companies in the very late stages of either drug or medical device development. They are first lien senior secured loans and typically are accompanied with success fees for warrants. Finally, our equipment finance business lends the companies with a high percentage of essential use fixed assets in need of capital expenditure financing. Solar entered this business through the acquisition of Nations Equipment Finance last year, which was founded in back in 2010 by former GE Capital’s senior executives. Included in this business our equipments financing held both directly on Solar’s balance sheet as well as in our wholly owned subsidiary NEF Holdings, which is set up for tax efficiency purposes for certain NEF investments. The addition of equipment financing to the Solar platform enables us to act as a full solution provider across a variety of asset based and cash flow products from middle market borrowers as well as our financial sponsor clients. In the aggregate, at year-end our investments across this four verticals totaled $1.66 billion, encompassing over 200 borrowers across more than 90 industries. Our average investment per issuer was $8 million, or 0.5% of the comprehensive portfolio. At year-end, just over 98% of our comprehensive portfolio consisted of senior secured loans. Of this amount approximately 77% was in first lien senior secured loans and approximately 21% was in senior secured second lien loans. Year-over-year, our second lien loan exposure declined by approximately 40% as we focused our origination efforts on first lien and stretch first lien senior secured loans to upper middle market sponsor-owned companies as well as our commercial finance portfolios. At year-end 80% of Solar's income producing portfolio was flooding rate. The fixed rate loan exposure principally comes from NEF’s short duration equipment financings with an average life of roughly 2.5 years and an average yield of 11% at year-end. Including investments and repayments across our four business lines, originations totaled approximately $160 million and repayments were approximately $180 million during the fourth quarter. Now let me provide an update on the credit quality and earnings power of our portfolio. Overall, the financial health of our portfolio remains sound, reflecting our disciplined underwriting and focus on downside protection. At year-end the weighted average investment risk rating of Solar's portfolio was two measured fair market value, based on our one to four risk rating scale with one representing the least amount of risk. Approximately 97% of our portfolio was rated either two or one, reflecting the portfolio’s strong credit fundamentals. In addition 100% of the portfolio was performing at 12/31. The weighted average yields on a fair value and current cost basis at year-end was 10.1% and 10.6% at cost, up slightly from the weighted average yields a year ago. Our diversified portfolio across both cash flow and asset based lending enable Solar to increase its overall yield in spite of a 50 to 100 basis point decline in year-over-year weighted average yields of our cash flow portfolio. We're very pleased with the performance of the portfolio companies and believe that it validates our prudent investment approach and strategic focus on lower risk cash flow and ABL investments. Now let me provide a brief update on our investment verticals. First, the cash flow business. At year-end, our cash flow loan portfolio was approximately $714 million, representing 43% of the overall portfolio. The weighted average trailing 12 month revenue and EBITDA trends were up mid to high single-digits, reflecting continued positive trends for our portfolio companies fundamentals. For the companies in our cash flow segment, leverage to our security on average was 5 times, debt to EBITDA consistent with the prior quarter, interest coverage was 2.5 times and average EBITDA was $64 million. The U.S. economic environment with stable earnings and low defaults continues to remain favorable for disciplined credit investors. During the fourth quarter, we originated senior secured cash flow investments of approximately $108 million, including $8 million in the SSLPs and had repayments of $36 million including $2.3 million in the SSLPs. The weighted average yield, the cash flow portfolio at year-end was just over 9%. A year ago, as I mentioned earlier, the weighted average yield was 50 to 100 basis points higher for cash flow loans, reflecting primarily our focus on originating lower risk first and stretch first lien senior secured loans. Now let me highlight a couple of our new cash flow investments. During the fourth quarter, Solar made a $90 million investment across the platform with SLRC funding $60 million in the first lien term loan of on locations experiences. The funding helped the company's acquisition of PrimeSport, which is a leading provider of premium hospitality services for high profile sporting event such as the Super Bowl, the NCAA Final Four and the U.S. Open. The U.S. -- the loan yields just over 7% on a first lien investment. In addition, we funded a $25 million investment in the first lien term loan of Zerto [ph] a leading provider of business continuity services and disaster recovery services for IT service providers. The yield on this loan is over 10%. Now let me turn to our asset base portfolio, Crystal. At year-end the senior secured asset base portfolio was just under $400 million, representing approximately 24% of our overall portfolio. The weighted average yield at costs of this portfolio was 10.2%. During the fourth quarter, we funded just over $24 million of new asset based investments and had repayments of just over $100 million. In addition, Crystal paid Solar, fourth quarter cash dividend of $7.9 million equating to an 11.3% yield on costs, consistent with the prior quarter. Turning to equipment finance. As a reminder, Solar had closely followed NEF for a number of years, given our investment activity in the leasing industry. In addition, senior members of our investment team have long standing relationships with NEF’s senior executives, as a number of both Solar and Crystal investment team members trained under NEF’s founder and CEO, Phil Carlson, while they were together back in GE Capital. Today NEF employs approximately 40 professionals. Since their inception, NEF has directly originated and funded approximately $1 billion of equipment financings. Collateral securing the portfolio consist of long life essential used assets, such as trucks, trailers, machine tools and equipment, which can be readily liquidated. Advance rates are typically below liquidation value and our loan tenure is typically three to seven years with an average life of just over two years. The typical customer of NEF is a privately owned mid-market business with a high percentage of fixed assets. With this 100% collateralized loan portfolio the addition of NEF to Solar complements our existing cash flow asset based and life science lending businesses. Importantly, we believe that NEF’s business is highly scalable and provides Solar access to a middle market asset class that offer very attractive risks adjusted returns, which are comparable to our other specialty finance businesses. At year-end, NEF had a total portfolio of approximately $310 million at fair value, lending to over 115 borrowers, with an average exposure of just over $2.5 million. The equipment finance asset class represents approximately 18.5% of our total portfolio. The weighted average yield at costs on this portfolio was 11.1%. During the fourth quarter, NEF had new investments of approximately $14 million and had amortization and repayments of approximately $31 million. 100% of NEF’s investments are first lien loans and approximately $280 million of the portfolio is fix rate. Interest rate is mitigated here through the relatively short holding period of 2.5 year duration, as well as our efforts to match fund this fix rate asset class both with our unsecured fix rate liabilities of approximately $250 million, as well as some interest rate tabs that bridge the gap. During the fourth quarter comprehensive net investment income from NEF’s portfolio totaled $5.4 million, which equates to an annualized yield on cost of approximately 10%. Now let me turn to life sciences. Our portfolio totaled approximately $213 million, across 23 borrowers with an average investment of $9.3 million at year-end. Life science loans represent just under 13% of our overall portfolio. During the fourth quarter the team originated $11.5 million of new senior secured loans and repayments totaled approximately the same, $11.7 million. The weighted average yield on our life science portfolio is 11.3% at fair value and 12.7% at cost, but this excludes exit and success fees and warrants. The blended IRR on our realized life science investments through year-end was 17.6% when including realized loss. As Michael mentioned, the middle market cash flow lending environment remains frosty given the market technicals. We benefit however, from our diversified origination sources, and we'll continue to be disciplined and prudent in deploying our available capital. Longer term, we believe that the record amounts of private equity capital raised to retreat of banks from middle market leverage lending and the approaching refinancing waves of existing leverage companies that need to refinance the balance sheet, creates an extremely attractive supply demand dynamic for cash flow lending to middle market companies, which we see as a way to augment our strength in commercial finance verticals. At this time, I'll turn the call back over to Michael.